Plasma Fractionation Market to Register Substantial Growth in Coming Years
Surge in geriatric
population and growing use of immunoglobulins in various therapeutic areas to
drive global plasma fractionation market
According to
TechSci Research report, “Global Plasma Fractionation Market By Product (Coagulation
Factors, Immunoglobins, Protease Inhibitor. Anticoagulants, Albumin), By Method
(Cohn Cold Fractioning Process, Chromatography, Cryoprecipitation, Others), By Plasma
Source (Blood Test, Plasmapheresis), By Test (NAT-testing, ELISA, Screening
Test), By Donor (Recovered Plasma, Source Plasma), By Application (Neurology,
Immunology, Hematology, Others), By End-User (Hospitals and Clinics, Clinical
Research Laboratories, Others), By Region, Competition, Forecast &
Opportunities, 2025”, the market is expected to register significant growth
owing to surging plasma collection with increase in number of plasma collection
centers and increasing use of alpha-1-antitrypsin. Furthermore, growing geriatric
population across the globe, which is susceptible to various rare diseases that
require the use of plasma derivatives, is also a major factor behind the growth
of global plasma fractionation market. Moreover, growing use of immunoglobulins
in various therapeutic areas is also fueling the growth of the plasma
fractionation market.
Additionally, increasing incidences of blood and
immune disorders among individuals along with increasing off-label usage of
critical plasma products such as albumins, and immunoglobulin are some other
major factors expected to boost the growth of global plasma fractionation
market in coming years. Increasing
incidences and prevalence of chronic diseases around the globe and rising
expenditure on advanced healthcare are some other factors responsible for the
rising demand of plasma fractionation. Also, there are governments encouraging
and creating awareness and availability of plasma-derived medicine products for
therapeutic usage, which is acting as a positive factor for the market growth.
However, there are some factors restricting the growth
of global plasma fractionation market. The high cost of plasma products might limit
the demand for plasma fractionation. Also, limited reimbursements and increasing
usage of recombinant proteins and products acting as a substitute for the
plasma products might also hamper the overall growth of global plasma
fractionation market.
Browse XX market data Tables and XX Figures spread
through XXX Pages and an
in-depth TOC on "Global Plasma Fractionation Market"
https://www.techsciresearch.com/report/plasma-fractionation-market/5091.html
The global plasma
fractionation market is segmented based on product, method, plasma source, test,
donor, application, end-user and region. Based on product, the market is
segmented into coagulation factors, immunoglobins, protease inhibitor,
anticoagulants and albumin. The coagulation factors segment is further divided
into factor VIII, factor IX, prothrombin, fibrinogen and others. Moreover, the
protease inhibitor segment is divided into Alpha-1-Antitrypsin and C1-inhibitor.
Among the products, the immunoglobins segment dominates the global plasma
fractionation market owing to wide usage of immunoglobulin in various disorders
such as primary and secondary immune deficiencies, autoimmune diseases, and
inflammatory diseases. Also, surge in research related to immunology across the
globe is another factor which is expected to drive the demand for
immunoglobulin in the coming years.
Based on
application, the global plasma fractionation market is segmented into neurology,
immunology, hematology and others. Among them, the neurology segment is
expected to dominate the market during the forecast period due to the surge in
the neurological disorders that require plasma fractionation products for
treatment. Further, increase in the adoption of plasma fractionation products
in the field of neurology is driving the growth of this segment in plasma
fractionation market.
Major players operating in the global
plasma fractionation market include Grifols, Baxter, CSL Behring, Bio Products
Laboratory, Biotest AG, China Biologic Products, Benesis Corporation, Kedrion
S.p.A, Octapharma, Shire, LFB, Sanquin, GC Pharma (Green Cross Corporation), Takeda
Pharmaceutical, Hualan Bio, Eli Lily, Roche, Bayer, Becton Dickinson and Intas
Pharmaceutical. The market players have adopted various strategies like collaboration,
product launch, partnership, and acquisition for garnering maximum market
share.
Download
Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5091
Customers can
also request for 10% free customization on this report.
“Increasing
research and development activities in plasma fractionation is leading to its
wide application various treatments. The presence of improvised and advanced
plasma fractionation facilities and centers around the world is also boosting
the market growth. However, the companies need to focus on brining
cost-effective and innovative methods to become a leading player in global
plasma fractionation market,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based global management consulting firm.
“Global Plasma Fractionation Market By Product
(Coagulation Factors, Immunoglobins, Protease Inhibitor. Anticoagulants,
Albumin), By Method (Cohn Cold Fractioning Process, Chromatography,
Cryoprecipitation, Others), By Plasma Source (Blood Test, Plasmapheresis), By Test
(NAT-testing, ELISA, Screening Test), By Donor (Recovered Plasma, Source
Plasma), By Application (Neurology,
Immunology, Hematology, Others), By End-User (Hospitals and Clinics, Clinical
Research Laboratories, Others), By Region, Competition, Forecast &
Opportunities, 2025” has evaluated
the future growth potential of global plasma fractionation market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global plasma fractionation market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]